Synchron Raises $200 Million Series D to Advance Brain-Computer Interface Technology

Synchron closed a $200 million Series D led by Double Point Ventures with participation from existing and new investors including Khosla Ventures, Bezos Expeditions, QIA, and others. The company will fund commercialization of its Stentrode endovascular BCI system—designed to translate brain activity to digital commands without open-brain surgery—and expand AI and engineering operations in New York and San Diego. Synchron noted placements in 10 patients to date across trials in the U.S. and Australia and said total funding now stands at approximately $345 million.